Lichen Planus (LP) is a complex inflammatory disease that is chronic in nature. It primarily impacts the skin, but may also affect the nails, scalp, oral and genital mucosa. The key cellular event in LP originates from cytotoxic CD8+T-cells, which are part of our immune system that protects us from disease.
Welling Homeopathy’s Natural Alternative To Otezla for Lichen Planus
Welling Homeopathy presents their CUREplus™ treatment, a comprehensive, personalized approach for lichen planus. CUREplus™ combines traditional homeopathy with modern science to address the root cause of the condition.
The treatment process is based on holistic practices, using gentle, natural homeopathic remedies tailored to the patient’s individual needs and circumstances. The therapy aims to modulate the immune system, potentially targeting the autoimmune reactions that are believed to manifest lichen planus. Welling Homeopathy bolsters its approach with up-to-date medical research, offering effective and targeted care. With an extensive history and recognition from a myriad of patients across 108 countries, CUREplus™ has shown a high level of success and patient satisfaction, making it a promising alternative for lichen planus.
Lichen Planus Due To Pfizer COVID-19 Vaccine
These CD8+ T-cells attack the basal keratinocytes – cells in the outermost layer of the skin. Ultimately, this autoimmune attack leads to inflammation and the characteristic purplish, itchy, flat-topped bumps one sees with lichen planus[1%5E].
Interestingly, vaccines have been associated with the emergence of LP in some instances. Specifically, vaccines for Hepatitis B and influenza have reportedly induced episodes of LP[4%5E]. The potential connection here is thought to be an immune response triggered by the vaccines that somehow results in the aforementioned cytotoxic T-cell overactivity.
More recently, new cases of LP have been reported following vaccination with the Pfizer-BioNTech COVID-19 vaccine[5%5E]. The vaccines mobilize the immune system to build protection against the SARS-CoV2 virus, and it is conjectured that this heightened state of immune activation may inadvertently trigger LP in certain individuals. However, this proposition still requires more research to confirm, yet these incidences present a crucial area of investigation for scientists aiming to understand vaccine effects better.
A study published in July 2021 highlighted the development of a new-onset lichen planus case triggered by the Pfizer-BioNTech COVID-19 vaccine[4%5E]. Another article published in September 2022 reported on a patient who developed new-onset LP 48 hours after the first dose of the vaccine, with symptoms exacerbating following the second dose[2%5E]. After treatment with topical corticosteroids, the patient’s LP was controlled within 21 days[2%5E]. Furthermore, a review on LP cases following COVID-19 infection and vaccination was presented in an article published in December 2022[3%5E].
Although the number of cases reported is limited and the exact relationship between LP and the COVID-19 vaccine remains to be fully understood, these findings offer a starting point for further research on the potential connection between lichen planus and COVID-19 vaccination.
